Eli Lilly reported lower-than-expected sales for its weight-loss and diabetes drugs, Zepbound and Mounjaro, as supplies sat in warehouses. The company had previously struggled to meet high demand, but ...
Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.